Phase I Platinum Based Chemotherapy Plus Indomethacin
NCT01719926
Adnexal Diseases, Colonic Diseases
Amsterdam, Netherlands
View Trial DetailsNCT Number: NCT01156831
The purpose of this study is to determine the locoregional control in PET/CT based radiotherapy treatment planning in the treatment of esophageal cancer patients.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Atrium Hospital, Heerlen, Netherlands
The purpose of this study is to determine the locoregional control in PET/CT based radiotherapy treatment planning in the treatment of esophageal cancer patients
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 2 years and 5 years
Time frame: 2 years and 5 years
Time frame: 2 years and 5 years
Time frame: At the time of surgery
Tumor regression grade at time of surgery evaluated by pathologist.
Maastricht Radiation Oncology
Other
Consequences of Positron-Emission-Tomography/Computed Tomography (PET/CT) Based Radiotherapy Treatment Planning for Clinical Outcome in Esophageal Cancer Patients
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01719926
Adnexal Diseases, Colonic Diseases
Amsterdam, Netherlands
View Trial DetailsNCT00213486
Digestive System Diseases, Digestive System Neoplasms
Rouen, France
View Trial DetailsNCT02359968
Digestive System Diseases, Digestive System Neoplasms
Angers, France
View Trial DetailsNCT06027515
Digestive System Diseases, Digestive System Neoplasms
Boston, Massachusetts, United States
View Trial Details